

**SENATE . . . . . No. 1096**

---

**The Commonwealth of Massachusetts**

PRESENTED BY:

***Jennifer L. Flanagan***

*To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:*

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

**An Act to expand access to medically assisted treatment providers.**

PETITION OF:

NAME:	DISTRICT/ADDRESS:	
<i>Jennifer L. Flanagan</i>	<i>Worcester and Middlesex</i>	
<i>Kimberly N. Ferguson</i>	<i>1st Worcester</i>	<i>2/3/2017</i>
<i>Kay Khan</i>	<i>11th Middlesex</i>	<i>2/3/2017</i>
<i>Julian Cyr</i>	<i>Cape and Islands</i>	<i>2/3/2017</i>
<i>Eileen M. Donoghue</i>	<i>First Middlesex</i>	<i>2/3/2017</i>

**SENATE . . . . . No. 1096**

---

---

By Ms. Flanagan, a petition (accompanied by bill, Senate, No. 1096) of Jennifer L. Flanagan, Kimberly N. Ferguson, Kay Khan, Julian Cyr and others for legislation to expand access to medically assisted treatment providers. Mental Health, Substance Use and Recovery.

---

---

**The Commonwealth of Massachusetts**

\_\_\_\_\_  
**In the One Hundred and Ninetieth General Court  
(2017-2018)**  
\_\_\_\_\_

An Act to expand access to medically assisted treatment providers.

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1           Section 1. The Department of Public Health and the Massachusetts Board of Registration  
2 in Medicine shall develop or provide for, and make available for voluntary participation by any  
3 physician, a professional training module on the prescribing and administration of naltrexone,  
4 both pill and injectable form, for the treatment of opioid use disorders and alcohol use disorders.

5 The training module shall include, but not be limited to guidelines and best practices for:

6           A.Assessment;

7           B.Care Coordination;

8           C.Treatment Plans, including counseling frequency and type;

9           D.Toxicology Screens;

10          E.Appropriate Length of Treatment; and

11 F.Relapse Prevention

12 The training module developed shall be accepted by the board as up to 2 continuing  
13 professional development credits.

14 Section 2. Notwithstanding any special or general law to the contrary, the Department of  
15 Public Health and the Bureau of Substance Abuse Services shall establish an extended release  
16 naltrexone training and technical assistance program for providers licensed or certified by the  
17 Department of Public Health. The Department shall prioritize training and ongoing technical  
18 assistance for providers serving cities and towns of the Commonwealth with greater than ten  
19 opioid related fatalities per ten thousand as documented in the study authorized by Chapter 55 of  
20 the Acts of 2015. The Department shall also evaluate and direct training to expand the number  
21 of providers serving individuals released from Department of Correction facilities and Houses of  
22 Correction. Provided further, that said training program shall include, but not be limited to the  
23 following criteria: patient eligibility, optimal selection criteria, placement matching, patient  
24 engagement, team coaching and coordination, withdrawal management and induction, dosing  
25 and administration, clinical evaluation and laboratory monitoring, side effect management, co-  
26 occurring disorders management, drug interactions, persistence management, managed care  
27 interactions, and termination of medication.

28 Section 3. The department of public health shall submit a report to the house and senate  
29 committees on ways and means and the joint committee on mental health and substance abuse on  
30 the number of providers trained and any identified obstacles to expanding the number of  
31 providers trained in extended release naltrexone by January 1, 2018.